{"id":"W3029830108","doi":"10.1016/j.clgc.2020.05.013","title":"A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; Astellas Pharma; Bayer Fund; Parker Institute for Cancer Immunotherapy; Sanofi; Exelixis; Genentech; Valeant Pharmaceuticals International; Merck; Astellas Pharma US; Society for Immunotherapy of Cancer; Prostate Cancer Foundation; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Sunitinib; Dasatinib; Prostate cancer; Hazard ratio; Internal medicine; Oncology; Abiraterone acetate; Clinical endpoint; Randomized controlled trial; Androgen deprivation therapy; Urology; Docetaxel; Confidence interval; Cancer; Tyrosine kinase","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001824019,0.002009579,0.002549521,0.0005912675,0.000603232,0.001110508,0.000876534,0.001768535,0.01034382],"category_scores_gemma":[0.002403958,0.0007958972,0.0019012,0.0004403495,0.001340607,0.001288416,0.000527668,0.004220924,0.001609179],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001060195,"about_ca_system_score_gemma":0.00205199,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001588857,"about_ca_topic_score_gemma":0.003886601,"domain_scores_codex":[0.9991168,0.0004193605,0.00004059512,0.0002026669,0.00004998612,0.0001704982],"domain_scores_gemma":[0.9987929,0.0003079633,0.0001800607,0.0001284801,0.00005351421,0.0005372097],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9745831,0.008579963,0.0003675974,0.0001553903,0.0003559288,0.00002728286,0.00005889778,0.0005894343,0.001672553,0.0001148547,0.0007562672,0.01273875],"study_design_scores_gemma":[0.928213,0.06911533,0.001017201,0.00001124498,0.0001348634,0.00003309291,0.00002132885,0.0004479339,0.0002757578,0.0002324063,0.0004814015,0.00001646579],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9871268,0.001643134,0.000847927,0.001071194,0.0008251343,0.004220964,0.001081214,0.0002096126,0.002974134],"genre_scores_gemma":[0.986178,0.0008894022,0.002098498,0.001039773,0.0003837157,0.004286164,0.00107822,0.00005092177,0.003995211],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01034382,"threshold_uncertainty_score":0.03460354,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1200264725992522,"score_gpt":0.4509374965081492,"score_spread":0.330911023908897,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}